Maternally derived RSV-specific antibodies play a role in protection against RSV infection in early life, but data regarding the concentration and specificity of those antibodies are incomplete.
Respiratory syncytial virus (RSV) is the leading etiologic agent of acute lower respiratory tract infection (LRTI) in infants and young children worldwide. In developed countries, it represents the primary cause of hospitalization in infants [1] [2] [3] [4] . After the first month of life, RSV is a major cause of infant mortality in the developing world, second only to malaria [5] . Each year, approximately 34 million children under the age of 5 develop severe RSV disease, 3.5 million of whom require hospitalization [1] . Despite the substantial disease burden caused by RSV, there is currently no licensed vaccine.
Protection against RSV can be conferred by neutralizing antibodies (nAbs), as demonstrated by the ability of palivizumab, a monoclonal antibody targeting the RSV fusion (F) glycoprotein, to prevent RSV-associated hospitalizations in high-risk infants [6, 7] . In addition, studies suggest that infants with high levels of naturally acquired nAbs are less likely to be hospitalized with severe disease [8] [9] [10] . The RSV fusion (F) protein and the attachment (G) protein are the major surface glycoproteins present on the virion. The F protein is present in 2 distinct conformations: the prefusion (pre-F) and postfusion (post-F) forms. Recent studies demonstrated that between these 2 conformations, the pre-F form displays more potent neutralizing epitopes than the post-F form [11] [12] [13] . The F protein, which is highly conserved across RSV strains, is considered to be the primary antigenic target for nAb and, therefore, a primary vaccine target [11, 14] . In contrast, the G protein has a high degree of genetic variability between RSV subgroups and is considered to be a less attractive vaccine target [15] .
Although recent advances in the field have shed light on the importance of pre-F nAb in the healthy adult population, the role of pre-F, post-F, and G antibodies in protecting infants from severe RSV disease requires investigation. Respiratory syncytial virus-specific antibodies are present in young infants and most likely are maternal in origin, yet RSV-associated LRTI is a common infection in these children, the majority of whom have no obvious pre-existing risk factors [16] [17] [18] [19] [20] [21] . As such, gaining a better understanding of which of these antibodies has the most significant impact on modulating disease severity in this vulnerable population is crucial. This is especially relevant now that the development of maternal vaccination for protecting young infants is being actively investigated [22] [23] [24] . In this study, we examined RSV-specific antibodies in infants and young children with mild and severe RSV infection to evaluate the role of pre-F, post-F, and G antibody concentrations and their neutralizing activity on RSV clinical disease severity.
MATERIALS AND METHODS

Study Subjects and Design
During 2 consecutive respiratory seasons (2013-14 and 2014-15), previously healthy infants and young children <2 years of age diagnosed with acute RSV infection were enrolled at the urgent care clinics or the emergency department (outpatients) or within 24 hours of hospitalization (inpatients) at Nationwide Children's Hospital (Columbus, OH). Age-matched, noninfected healthy controls were also enrolled, and samples were obtained at well-child visits or during minor elective surgical procedures not involving the respiratory tract, as described previously [25] [26] [27] . Blood and nasal wash samples were collected at enrollment for all patients and controls. Nasal wash samples were used for RSV confirmation and quantification by real-time polymerase chain reaction [27] . Serum samples were used to measure RSV antibody concentrations by enzyme-linked immunosorbent assay (ELISA) and virus neutralization activity. Patients were excluded from the study if they were born prematurely (<36 weeks), had chronic medical conditions (ie, congenital heart or chronic lung disease), or had history of immunodeficiency. This study was approved by the Institutional Review Board (IRB) at Nationwide Children's Hospital (IRB no. 10-00028), classified as a Level 1 risk clinical study-no greater than minimal risk (pursuant under 45 Code of Federal Regulations [CFR], part 46.404 and 21 CFR, part 50.51). Informed consent procedures were followed in compliance with the Nationwide Children's Research Responsible Conduct Guidelines.
Demographic and Clinical Parameters
Demographic and clinical parameters were collected during the infant's physical examination using a standardized questionnaire. Disease severity was assessed using several parameters, including a standardized clinical disease severity score (CDSS), the need for hospitalization, and duration of hospital stay (length of stay [LOS] ) in hospitalized children [27] [28] [29] . The CDSS was assessed at the time of enrollment and ranged from 0 (normal) to 15 (most severe) [29] .
Cell Culture and Virus
A549 cells obtained from the American Type Culture Collection (Manassas, VA) were maintained in Dulbecco's modified Eagle's medium (DMEM) with 10% fetal bovine serum (FBS) supplemented penicillin and streptomycin. Freestyle 293-F suspension cells were maintained in serum-free Freestyle 293 Expression media and cultured as described previously (Thermo Fisher Scientific). Recombinant luciferase expressing RSV (Luc-RSV) has been previously described [30] .
Plasmids
The RSV F and G proteins from RSV strain A2, clone D53, were codon-optimized, lack their transmembrane and cytoplasmic domains, and were expressed from the pcDNA3.1 plasmid. The pre-F trimer contained the stabilizing DS-Cav1 mutations [31] ; the post-F protein did not [32] . The N-terminal transmembrane and cytoplasmic domains of the G protein were replaced with the N-terminal region of the Schwarz measles virus H protein followed by a furin cleavage site to facilitate expression and secretion.
Transfection and Purification of the Respiratory Syncytial Virus F and G
Proteins
Freestyle 293-F cells were grown in suspension and transfected with plasmids expressing the soluble RSV F or G proteins. The pre-F and post-F proteins were captured with agarose-Ni 2+ slurry (ProBond Purification System), washed, eluted [32] , concentrated, and further purified by size-exclusion chromatography on a HiLoad Superdex 200pg gel filtration column (GE Healthcare). The G protein was captured using agarose-bound wheat germ agglutinin (WGA) (Vector Laboratories), washed extensively with 0.15 M NaCl, 10 mM HEPES (pH 7.5), and eluted with chitin hydrolysate (1:10 dilution) in 0.15 M NaCl, 10 mM HEPES (pH 3.0). The eluate was concentrated and further purified by size-exclusion chromatography as described above. Protein concentrations and purity were determined by using the Nanodrop 2000c (Thermo Fisher). Proteins were separated on polyacrylamide gels. F was stained with Coomassie brilliant blue and G with the Glycoprotein Staining Kit (Pierce). Protein purity was estimated to be >95%.
Enzyme-Linked Immunosorbent Assay
Indirect ELISAs were developed for the detection and quantification of immunoglobulin (Ig)G to pre-F, post-F, and G proteins. Ni 2+ chelate-coated 96-well flat-bottom plates (Pierce) were coated with 2.5 µg/mL pre-F, post-F, or G proteins, washed with phosphate-buffered saline (PBS), 0.05% Tween 20, and blocked with wash buffer containing 2% milk. Serum samples diluted in blocking buffer were added, plates were washed and incubated with 125 ng/mL goat antihuman IgG conjugated to horseradish peroxidase, followed by 3,3' ,5,5'-tetramethylbenzidine. Color development was stopped with sulfuric acid, and the absorbance was quantified at 450 nm with a PE Wallac Victor 2 1420-012 microplate reader. Antibody titers in the linear range (0.5-1.5 OD 450 ) were converted to µg/mL IgG from a standard curve of serially diluted human reference serum containing a known concentration of IgG (Bethyl Laboratories) assayed in parallel. Microplates had a background absorbance at 450 nm of 0.25. Patients reported as having no detectable antibody concentrations had absorbance values at 450 nm of 0.25 or less, which are indistinguishable from background and therefore below the limit of detection for the assay. Avidity was determined by including a 10-minute wash with urea (7 M), after incubation of serum samples [33, 34] .
Virus Neutralization Assay
Serum samples were heat inactivated at 65°C for 30 minutes and diluted 1:10 and serially 4-fold before adding an equal volume of 250 plaque-forming units of Luc-RSV to each dilution [30] and incubating at 22°C for 1 hour and inoculating A549 cells in 96-well culture plates. The inoculum was replaced with DMEM, 2.5% FBS, incubated for 16 hours at 37°C, lysed, substrate was added (Renilla Luciferase Assay System; Promega), samples were transferred to 96-well solid black plates, and luminescence was quantified with the microplate reader. For the serum adsorption assay, serum samples were diluted 1:10 in Dulbecco's PBS ([DPBS] HyClone) and incubated with an equal volume of pre-F, post-F, or G proteins (15 µg/mL), or DPBS buffer alone. Agaroseconjugated WGA was added, incubated at 4°C, and the beads with their absorbed viral glycoproteins complexed with IgG were removed by centrifugation before testing neutralization.
Statistical Analysis
Descriptive analyses and frequency distributions were used to summarize the patient demographic and baseline characteristics. Groups (inpatients, outpatients, and controls) were compared using χ 2 or Fisher exact test for categorical variables and Kruskal-Wallis or Mann-Whitney test for continuous variables. Correlations were calculated using Spearman's rank correlation coefficient, because most data did not follow a normal distribution. The median inhibitory concentration (IC 50 ) was calculated by curve fitting and nonlinear regression analysis. For all analyses, results with a 2-sided P < .05 were considered significant. Statistical analyses were performed using GraphPad (La Jolla, CA) Prism Software for Windows, version 6.00.
RESULTS
Clinical Characteristics of Study Subjects
Serum samples from 65 children with acute RSV infection (45 hospitalized, 20 outpatients) and 18 healthy controls were analyzed. Children with RSV disease were enrolled during the acute phase of the infection, with a median of 4.9 days after the onset of illness for hospitalized patients and 5.7 days for outpatients. Clinical and demographic data for patients and controls are shown in Table 1 . Patients hospitalized with RSV infection were significantly younger (median age, 2.2 months) compared with outpatients (6.9 months) and with healthy controls (4.4 months). The mean RSV load was 5.1 ± 1.3 log 10 copies/ mL, and RSV loads were comparable between inpatients and outpatients. Likewise, the proportion of RSV A and B infections were not significantly different in inpatients compared with outpatients. Among hospitalized patients, 39 (87%) were admitted to the inpatient ward and 6 (13%) required admission to the pediatric intensive care unit. The median LOS for hospitalized patients was 1.9 (interquartile range, 1.2-3.1) days.
Respiratory Syncytial Virus (RSV)-Specific Antibodies, Neutralizing
Activity, and Age in RSV-Infected Patients
For analyses, children were stratified by age: 0 to 2 months, >2 to 4 months, >4 to 6 months, and >6 months (Figure 1) . Antibodies against the pre-F protein had the highest concentrations in all age groups, for both RSV-infected patients and healthy controls. In RSV-infected children 0 to 4 months of age, antibody concentrations to the pre-F protein were >3-fold higher than post-F antibodies and >30-fold higher than antibodies to the G protein. Antibody concentrations appeared lower in patients than in healthy controls for most age groups; however, the small number of healthy controls in each group precluded statistical comparisons between patients and healthy controls.
Antibody concentrations against all 3 RSV glycoproteins (pre-F, post-F, and G) were greatest in infants 0 to 2 months of age and inversely correlated with age at the time of infection (pre-F and post-F, P < .0001; r = −0.66; G, P < .0001; r = −0.52). e A sample in the inpatient cohort was not evaluated for RSV A or B.
f RSV loads are expressed in log 10 copies/mL.
Antibody concentrations to these RSV proteins had dramatically decreased in most RSV-infected infants by 4 to 6 months of age. In fact, 28%, 52%, and 76% of patients >4 months of age had no detectable antibodies to the pre-F, post-F, and G proteins, respectively. This decline in antibody concentration is consistent with the expected decay of maternally transferred antibodies with increasing age [18, 38] . A few of the older children and healthy controls >6 months of age (between 19 and 24 months) had high serum antibody concentrations. These children either attended day care or had siblings, suggesting that the elevated antibody concentrations observed likely represent the result of a previous RSV infection [19] .
To quantify the biological function of the RSV antibodies in these serum samples, we measured their ability to neutralize RSV in vitro [30] . As illustrated in Figure 1D , overall the serum neutralizing activity was not significantly different between patients and healthy controls, stratified by age. Like RSV-specific antibody concentrations, neutralization activity inversely correlated with age (P < .0001; r = −0.73).
Concentrations of Respiratory Syncytial Virus-Specific Antibodies and
Clinical Disease Severity
Next, we determined whether there was an association between disease severity and antibody concentrations. We excluded PostF-Specific Serum IgG (μg/ml) from these analyses outpatients with RSV infection because the median age at enrollment for these children was 7 months, and antibody concentrations (maternally derived) had decreased to essentially undetectable levels after the first 6 months of life. Thus, our analyses focused on RSV-infected hospitalized infants ≤6 months of age. Disease severity was assessed by using a standardized CDSS that included (1) a number of parameters reflecting the degree of respiratory distress (administration of supplemental oxygen, auscultation, tachypnea, or retractions) and (2) the general status of the patient as reflected by the ability to be fed or the need for intravenous fluids [29] . A high CDSS score indicates a more severe disease. Patients were divided into 2 groups, those with low CDSS (score 0-5; n = 20) and those with high CDSS (score 6-15; n = 18) ( Table 2 ). Patients with high CDSS (severe disease) required longer hospitalization and had a greater need for supplemental oxygen administration.
Antibody concentrations against each RSV antigen were compared between the low and high CDSS groups. Patients with mild disease had significantly higher concentrations of pre-F and G antibodies than those with severe disease (P = .038 and P = .028, respectively), whereas the difference in post-F antibodies between the groups was not significant (P = .133) (Figure 2 ). Likewise, neutralizing activity in patients with mild disease was higher than in patients with severe disease (7.6 vs 6.2 log 2 , respectively; P = .042).
Prefusion, Postfusion, and G Proteins as Targets of Neutralizing
Antibodies in Respiratory Syncytial Virus-Infected Infants
To identify the most important target for nAb, we adsorbed each individual patient serum separately with each of the pre-F, post-F, or G proteins. Each preadsorbed serum was assayed for its remaining neutralizing activity. Relatively large quantities of serum are required for this assay, and, as a result, only 16 patients ≤4 months of age, all hospitalized, could be assessed.
Adsorption with the pre-F protein removed neutralizing activity from serum samples obtained from all patients ( Figure  3A) . Neutralizing activity was reduced 55% to 100% (median reduction, 79% by adsorption with pre-F), the greatest amount of neutralizing activity removed by any of the 3 antigens, indicating that pre-F nAbs are responsible for the largest proportion of serum neutralizing activity. By comparison, adsorption with the post-F protein reduced neutralization in only 38% of patients, by 0% to 29% (median reduction, 0%). Adsorption with the G protein reduced neutralization in 63% of the patients' sera, by 0% to 45% (median reduction, 9%).
The higher number of patients with nAb against G and the higher proportion of neutralizing activity removed by adsorption with G compared with post-F were unexpected because post-F antibody concentrations were 8-fold greater than those observed for G antibodies (Figure 1 ). Greater neutralizing activity from fewer antibodies could be due to differences in the avidities of these antibody populations. To examine this possibility, avidity was defined as low (≤50.0%), intermediate (>50.0%-69.9%), or high (≥70.0%) [35] , and assessed ( Figure 3B ). The pre-F antibody median avidity was 71%, within the high avidity range, whereas the post-F antibody median avidity was 57%, in the intermediate avidity range, demonstrating a significant difference between pre-F and post-F avidity (P < .01). The G antibody median avidity was 64%, also in the intermediate avidity range, a difference that was not statistically significant when compared with pre-F or post-F (P > .05).
DISCUSSION
Infants are particularly vulnerable to developing severe RSV infection during the first months of life. Studies suggest that passive transfer of maternal antibodies can offer some protection against severe RSV infection [18, 20, 36, 37] . However, the antigenic specificity of these transferred antibodies that will confer the best protection against severe disease is not well defined. Accordingly, we studied the concentration, neutralizing activity, and impact on disease severity of pre-F, post-F, and G antibodies in young infants with acute RSV infection and in healthy asymptomatic control infants as a reference.
We found that antibody concentrations against all 3 viral proteins were greatest in patients ≤2 months of age. For all 3 RSV antigens, antibody concentrations declined to largely undetectable levels by 4-6 months of age. This is consistent with previous studies that have shown that infants with high concentrations of maternally derived antibodies can maintain detectable antibody concentrations for up to 6 months [18, 38] . Similar results were observed with respect to the neutralizing activities of these antibodies. Furthermore, when neutralizing activity was examined in the context of mild disease (low CDSS) vs severe disease (high CDSS), we found that patients with mild disease had higher concentrations of nAb than patients with more severe disease. Although previous studies have found that high concentrations of nAbs (≥7.5, log 2 ) are associated with decreased disease severity and protection against hospitalization in young children, others have failed to identify such associations, perhaps due to differences in study design, assays used, or sample size [20, 38, 39] .
Our findings also revealed that antibodies to the pre-F form of the F protein are both the most abundant and the most effective at neutralizing RSV. This is consistent with a previous study that found that pre-F antibodies are the major component of the neutralizing activity in healthy adults [11] . In addition, we found that patients with mild disease had higher concentrations of pre-F antibodies, indicating that pre-F antibodies are associated with less severe disease.
We also found that the neutralizing activity of G antibodies correlated with less severe disease in these young infants. Although G antibodies were found in lower concentrations than pre-F and post-F antibodies, they may play a role in reducing disease severity. These findings suggest that patients who also have serum nAb capable of targeting the G protein may be better protected against severe disease than patients with nAbs that only target the pre-F protein. This finding may have implications for designing vaccine candidates and should be considered in future studies. In contrast, despite observing high serum IgG concentrations against the post-F protein, these antibodies contributed little to the overall neutralizing capacity of patient sera and did not correlate with disease severity. One possibility for these results is that these post-F antibodies were of overall low to intermediate avidity and, as a result, poor neutralizers of viral infection [33, 34] .
Our study has limitations. First, due to the limited sample volume available for analysis, we were only able to perform the adsorption experiments on a subset of patients. However, even with this sample size, we were able to confirm that pre-F antibodies represent the largest proportion of serum neutralizing activity, similar to previous studies [11, 39] . Second, our analyses using the G protein only targeted the RSV A subtype. The use of a G protein from the RSV B subtype may have revealed an even greater contribution of G-specific nAbs, by detecting strain-specific antibodies that primarily target the C-terminal third of the G protein ectodomain [15] . Furthermore, the level of neutralization observed might have been different if we had sufficient sample volume to examine neutralization on primary, well differentiated human airway epithelial (HAE) cultures. Assessing neutralization on HAE cultures may be important because the G protein uses a different receptor on HAE cultures, presumably the same receptor that is used by RSV in vivo, rather than heparan sulfate, the receptor present on immortalized cells [40] . Nevertheless, we have tested this possibility in a previous study with two serum samples from healthy adults and did not find major differences in the neutralizing capacity of those serum samples when evaluated in the two cell culture models [11] .
CONCLUSIONS
In summary, we examined the impact of pre-F, post-F, and G antibodies on disease severity, in the context of acute RSV infection in infants and young children. Our findings confirmed that although pre-F is the major viral target for nAbs to RSV, the G protein is also important. These findings may have implications for RSV vaccine development.
Notes
